Neurofibromatosis type I and smoldering multiple myeloma: a case report

We present a case of a 64-year-old woman with neurofibromatosis (NF1) and smoldering multiple myeloma (SMM). SMM was diagnosed 9 years ago when the asymptomatic patient was found to have mild anemia, IgA paraproteinemia, hypogammaglobulinemia, osteopenia without any lytic bone lesions and bone marro...

Full description

Saved in:

Bibliographic Details
Published in:	Hematology (Luxembourg) Vol. 11; no. 1; p. 45
Main Authors:	Danilatou, Vassiliki, Liapi, Demetra, Psyllaki, Maria, Chatzivasili, Aria, Chronaki, Irini, Heliakis, Polyvios
Format:	Journal Article
Language:	English
Published:	England 01-02-2006
Subjects:	Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Diphosphonates - administration & dosage Diphosphonates - adverse effects Female Femoral Fractures - chemically induced Humans Immunoglobulin A - blood Middle Aged Multiple Myeloma - blood Multiple Myeloma - drug therapy Multiple Myeloma - etiology Multiple Myeloma - pathology Neurofibromatosis 1 - blood Neurofibromatosis 1 - complications Neurofibromatosis 1 - drug therapy Neurofibromatosis 1 - pathology Paraproteins - analysis
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We present a case of a 64-year-old woman with neurofibromatosis (NF1) and smoldering multiple myeloma (SMM). SMM was diagnosed 9 years ago when the asymptomatic patient was found to have mild anemia, IgA paraproteinemia, hypogammaglobulinemia, osteopenia without any lytic bone lesions and bone marrow plasmacytosis. During follow-up period she remained stable in an excellent clinical condition without requiring any therapy for almost 4 years. Forty-two months after diagnosis she had a femoral fracture and since then biphosphonates have been administered intravenously, once monthly. Subsequent evaluations of the disease showed a dramatic reduction of IgA paraprotein to below half the initial value. We will discuss the probable pathogenesis of plasma cell dyscrasia in NF1 patients, as well as the likely antimyeloma activity of biphoshonates.
ISSN:	1024-5332
DOI:	10.1080/10245330500328427